Morgan Stanley’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-22,765
| Closed | -$89.2K | – | 8060 |
|
|
2023
Q3 | $89.2K | Buy |
22,765
+17,059
| +299% | +$116K | ﹤0.01% | 5944 |
|
|
2023
Q2 | $18.5K | Buy |
5,706
+2,775
| +95% | +$8.25K | ﹤0.01% | 6597 |
|
|
2023
Q1 | $10.6K | Sell |
2,931
-1,014
| -26% | -$15.7K | ﹤0.01% | 6868 |
|
|
2022
Q4 | $127K | Buy |
3,945
+729
| +23% | +$28.9K | ﹤0.01% | 5871 |
|
|
2022
Q3 | $134K | Sell |
3,216
-3,762
| -54% | -$172K | ﹤0.01% | 5929 |
|
|
2022
Q2 | $294K | Buy |
6,978
+4,463
| +177% | +$207K | ﹤0.01% | 5698 |
|
|
2022
Q1 | $171K | Sell |
2,515
-7
| -0.3% | -$583 | ﹤0.01% | 6008 |
|
|
2021
Q4 | $306K | Sell |
2,522
-1,485
| -37% | -$251K | ﹤0.01% | 5833 |
|
|
2021
Q3 | $564K | Buy |
4,007
+1,346
| +51% | +$267K | ﹤0.01% | 5418 |
|
|
2021
Q2 | $732K | Sell |
2,661
-740
| -22% | -$187K | ﹤0.01% | 5268 |
|
|
2021
Q1 | $728K | Sell |
3,401
-1,180
| -26% | -$326K | ﹤0.01% | 4930 |
|
|
2020
Q4 | $1.11M | Buy |
4,581
+1,942
| +74% | +$240K | ﹤0.01% | 4599 |
|
|
2020
Q3 | $279K | Buy |
2,639
+276
| +12% | +$25.1K | ﹤0.01% | 4935 |
|
|
2020
Q2 | $231K | Buy |
2,363
+32
| +1% | +$2.8K | ﹤0.01% | 5011 |
|
|
2020
Q1 | $175K | Sell |
2,331
-409
| -15% | -$38.9K | ﹤0.01% | 4922 |
|
|
2019
Q4 | $223K | Sell |
2,740
-953
| -26% | -$107K | ﹤0.01% | 5368 |
|
|
2019
Q3 | $451K | Buy |
3,693
+483
| +15% | +$66.4K | ﹤0.01% | 4732 |
|
|
2019
Q2 | $576K | Buy |
3,210
+418
| +15% | +$67.6K | ﹤0.01% | 4530 |
|
|
2019
Q1 | $447K | Sell |
2,792
-41
| -1% | -$8.12K | ﹤0.01% | 4602 |
|
|
2018
Q4 | $737K | Buy |
2,833
+372
| +15% | +$74.9K | ﹤0.01% | 4517 |
|
|
2018
Q3 | $600K | Buy |
2,461
+1,572
| +177% | +$411K | ﹤0.01% | 4888 |
|
|
2018
Q2 | $210K | Buy |
+889
| New | +$259K | ﹤0.01% | 5512 |
|
Other funds holding EVLO
Morgan Stanley's EVLO Position: Q4 2023 in Review
Morgan Stanley sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 22,765 shares — an estimated $89.2K sold.
Morgan Stanley first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $1.11M in Q4 2020. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Morgan Stanley reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Morgan Stanley sold 22,765 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $89.2K.
- Morgan Stanley first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Morgan Stanley's Evelo Biosciences, Inc. Common Stock position peaked at $1.11M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.